Walgreens Boots Alliance, Inc. (WBA): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la atención médica y el comercio minorista, Walgreens Boots Alliance (WBA) surge como una potencia transformadora, combinando sin problemas los servicios de farmacia tradicionales con soluciones de salud digitales de vanguardia. Al aprovechar estratégicamente un modelo de negocio intrincado que abarca los mercados globales, la AMB se ha posicionado como algo más que una farmacia: es un ecosistema de atención médica integral que conecta a pacientes, proveedores y tecnologías de bienestar a través de canales innovadores y experiencias personalizadas. Esta profunda inmersión en el lienzo de modelo de negocio de la AMB revela el sofisticado marco estratégico que impulsa a uno de los minoristas de atención médica y farmacia más grandes del mundo.

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocios: asociaciones clave

Alianza estratégica con AmerisourceBergen

Walgreens Boots Alliance posee una participación de capital del 30% en AmerisourceBergen Corporation. En el año fiscal 2023, la asociación generó $ 25.4 mil millones en ingresos por distribución farmacéutica. La alianza estratégica proporciona servicios de distribución farmacéutica en los Estados Unidos.

Detalles de la asociación	Métricas financieras
Estaca de propiedad	30% en AmerisourceBergen
Ingresos por distribución	$ 25.4 mil millones (2023)
Duración de la asociación	En curso desde 2013

Asociaciones de fabricantes farmacéuticos y desarrolladores de drogas

Walgreens colabora con múltiples fabricantes farmacéuticos para garantizar el suministro y distribución de medicamentos.

• Pfizer: socio de distribución de vacunas Covid-19
• Johnson & Johnson: Vacunación y colaboración de la cadena de suministro farmacéutico
• Moderna: red de distribución de vacunas

Colaboraciones de la empresa de tecnología de la salud

Walgreens tiene asociaciones de tecnología estratégica con compañías de salud digital:

Socio tecnológico	Enfoque de colaboración
Microsoft	Soluciones de computación en la nube y salud digital
Veragemd	Desarrollo de la clínica de atención primaria
Salud de teladoc	Integración del servicio de telesalud

Asociaciones internacionales de redes de farmacia y atención médica

Walgreens Boots Alliance opera asociaciones internacionales a través de su red global.

• Alliance Boots (Reino Unido): Pharmacy Retail Network
• Grupo de tenencia de Sinopharm (China): distribución farmacéutica
• Farmacias Benavides (México): expansión de la farmacia minorista

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocio: actividades clave

Operaciones de farmacia minorista en varios países

A partir de 2024, Walgreens Boots Alliance opera 9.021 ubicaciones de farmacia minorista en los Estados Unidos e internacionalmente. La compañía administra 8,965 tiendas en los Estados Unidos y 56 tiendas internacionalmente.

País	Número de tiendas	Servicios de farmacia
Estados Unidos	8,965	Llenado de recetas, servicios de salud
Mercados internacionales	56	Pharmacy Retail, Servicios de atención médica

Distribución farmacéutica y servicios al por mayor

La AMB genera $ 25.4 mil millones en ingresos farmacéuticos mayoristas y de distribución a través de su asociación AmerISourceBergen, lo que representa el 15.3% de los ingresos totales de la compañía.

Servicios de atención médica y soluciones de salud digital

• Plataforma de atención virtual que atiende a 4.2 millones de consultas de salud digital en 2023
• Servicios de telesalud integrados en 50 estados
• Plataforma de gestión de prescripción digital con 12.3 millones de usuarios activos

Gestión de medicamentos recetados

Métrico	Volumen anual
Recetas totales llenas	1.08 mil millones
Transferencias de prescripción digital	376 millones
Programas de adherencia de medicamentos	287 millones de intervenciones

Merchandising de productos minoristas y gestión de inventario

WBA administra una cartera de inventario valorada en $ 17.6 mil millones, con 45,000 SKU de productos únicos en categorías de atención médica, bienestar y minorista.

Categoría de productos	Valor de inventario	Porcentaje de total
Farmacéuticos	$ 8.3 mil millones	47%
Salud y bienestar	$ 5.7 mil millones	32%
Bienes de consumo minoristas	$ 3.6 mil millones	21%

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocios: recursos clave

Extensa red de ubicaciones de farmacia

A partir de 2024, Walgreens opera 9.021 ubicaciones de farmacia minorista en todo Estados Unidos. La empresa mantiene 8,618 tiendas en los EE. UU. y 403 ubicaciones en mercados internacionales.

Tipo de ubicación	Número de tiendas
Farmacias minoristas de EE. UU.	8,618
Ubicaciones internacionales	403
Ubicaciones totales de farmacia	9,021

Plataformas y tecnologías de salud digital avanzadas

Walgreens ha invertido $ 1.2 mil millones en tecnologías de salud digital en 2023. Las plataformas digitales clave incluyen:

• Aplicación móvil Walgreens
• Sistema de gestión de recetas digitales de farmacia
• Plataforma de servicios de telesalud

Fuerte reputación de marca en el comercio minorista farmacéutico

Valor de la marca Walgreens estimado en $ 15.3 mil millones en 2024, clasificación 37º en valor de marca entre las marcas minoristas globales.

Profesionales y farmacéuticos de atención médica calificados

Walgreens emplea aproximadamente 283,000 empleados en total, con Más de 62,000 farmacéuticos con licencia a través de su red.

Categoría de empleado	Número de empleados
Total de empleados	283,000
Farmacéuticos con licencia	62,000

Infraestructura robusta de cadena de suministro y distribución

Walgreens mantiene 22 centros de distribución en todo Estados Unidos, con una capacidad de distribución anual de $ 132 mil millones en productos farmacéuticos y minoristas.

• Ubicaciones de centros de distribución total: 22
• Capacidad de distribución anual: $ 132 mil millones
• Tecnología de gestión de inventario: RFID avanzado y sistemas impulsados ​​por IA

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocio: propuestas de valor

Servicios de salud convenientes y accesibles

A partir del primer trimestre de 2024, Walgreens opera 9.021 ubicaciones de farmacia minorista en los Estados Unidos. La compañía proporciona:

• Servicios clínicos sin cita previa en más de 400 ubicaciones de la clínica de atención médica
• Covid-19 y servicios de vacunación de rutina en 8,945 tiendas
• Consultas de telesalud digital 24/7 a través de la plataforma en línea de Express Care

Tipo de servicio	Interacciones anuales del paciente	Costo promedio
Visitas en la clínica en la tienda	5.2 millones	$85-$125
Telesalud digital	3.7 millones	$49-$79

Soluciones integrales de medicamentos y bienestar

Los servicios farmacéuticos de Walgreens incluyen:

• Gestión de medicamentos recetados para 350 millones de recetas anuales
• Manejo de la terapia de medicamentos para 2.5 millones de pacientes
• Servicios de farmacia especializada que generan $ 22.3 mil millones en ingresos anuales

Experiencias integradas de farmacia digital y física

Métricas de plataforma digital:

• Aplicación móvil Walgreens con 70 millones de usuarios activos
• Tasa de recarga de prescripción digital: 45% de las recetas totales
• Ingresos de servicios de salud en línea: $ 1.6 mil millones en 2023

Ofertas de productos personalizados de salud y bienestar

Categoría de productos	Venta anual	Cuota de mercado
Productos de bienestar de la etiqueta privada	$ 3.4 mil millones	12.5%
Suplementos para la salud	$ 1.9 mil millones	8.7%

Programas competitivos de precios y fidelización de clientes

Detalles del programa de fidelización:

• Balance Programa de recompensas con 87 millones de miembros activos
• Ahorro promedio de clientes: $ 268 anualmente
• Redención de cupones digitales: 42% de las transacciones totales

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocios: relaciones con los clientes

Programas de fidelización y seguimiento de salud personalizado

El programa Walgreens Balance Rewards tenía 89 millones de miembros activos a partir de 2022. El programa genera aproximadamente $ 16.5 mil millones en ingresos por lealtad del cliente anualmente. Los miembros reciben un seguimiento de salud personalizado a través de la aplicación, con más de 4.5 millones de participantes activos de seguimiento de salud digital.

Métrica del programa de fidelización	Valor
Miembros activos	89 millones
Ingresos de lealtad	$ 16.5 mil millones
Usuarios de seguimiento de salud digital	4.5 millones

Plataformas de gestión de recetas digitales

Procesos de plataforma de prescripción digital de Walgreens 350 millones de recetas anualmente. La aplicación móvil tiene 70 millones de usuarios registrados con capacidades de gestión de prescripción digital.

• Solicitudes de recarga de prescripción digital: 42% de las interacciones totales de prescripción
• Inicios de sesión promedio de la aplicación mensual: 12.3 millones
• Programación de recolección de prescripción digital: disponible en 9.021 ubicaciones de farmacia

Servicios de consulta y evaluación de salud en la tienda

Walgreens realiza aproximadamente 5.2 millones de exámenes de salud anualmente en sus 9.021 ubicaciones. La compañía ofrece Administración de vacunas en 8,700 ubicaciones de tiendas.

Servicio de salud	Volumen anual
Exámenes de salud	5.2 millones
Lugar de vacuna	8,700

Aplicación móvil y atención al cliente en línea

Walgreens Mobile Application tiene 70 millones de usuarios registrados con una calificación de 4.7 estrellas. La atención al cliente maneja aproximadamente 22 millones de interacciones digitales mensualmente.

• Tasa de descarga de la aplicación móvil: 2.3 millones de nuevos usuarios por trimestre
• Disponibilidad de soporte de chat en línea: 24/7
• Tiempo de respuesta de servicio al cliente digital promedio: 8 minutos

Comunicación continua de compromiso de salud y bienestar

Walgreens envía 145 millones de puntos de contacto de comunicación de salud personalizados trimestralmente, con el 68% de los clientes que reciben recomendaciones de bienestar dirigidas.

Métrico de compromiso	Valor
Puntos de contacto de comunicación trimestrales	145 millones
Clientes que reciben recomendaciones específicas	68%

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocios: canales

Ubicaciones físicas de farmacia minorista

A partir del primer trimestre de 2024, Walgreens opera 9.021 ubicaciones de farmacia minorista en los Estados Unidos.

Tipo de ubicación	Número de tiendas
Tiendas Walgreens (EE. UU.)	9,021
Farmacias de botas (Reino Unido)	2,172
Ubicaciones internacionales	517

Plataformas de comercio electrónico en línea

Walgreens.com genera aproximadamente $ 5.2 mil millones en ventas digitales anuales a partir de 2023.

• Tasa de crecimiento de las ventas digitales: 27% año tras año
• Recargas de receta en línea: 68% del volumen total de prescripción
• Base de clientes digitales: 94 millones de usuarios registrados

Aplicación móvil

Las descargas de aplicaciones móviles de Walgreens llegaron a 45.3 millones de usuarios activos en 2023.

Métrica de la aplicación	Valor
Descargas totales de aplicaciones	45.3 millones
Usuarios activos mensuales	22.7 millones

Servicios de telesalud

La plataforma de atención virtual Walgreens realizó 3.2 millones de consultas de telesalud en 2023.

• Costo promedio de consulta de telesalud: $ 49
• Cobertura de servicio de telesalud: 48 estados
• Duración de consulta promedio: 12 minutos

Atención al cliente en la tienda y digital

Walgreens Atención al cliente maneja 12.5 millones de interacciones con el cliente mensualmente.

Canal de soporte	Interacciones mensuales
Soporte en la tienda	6.3 millones
Soporte digital	4.7 millones
Soporte telefónico	1.5 millones

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocios: segmentos de clientes

Consumidores de farmacia minorista

A partir de 2023, Walgreens atiende a aproximadamente 9 millones de clientes diariamente en 9.021 ubicaciones minoristas en los Estados Unidos. El valor promedio de la transacción del cliente es de $ 24.37.

Demográfico del cliente	Porcentaje
Edad 18-34	22%
Edad 35-54	35%
Edad 55+	43%

Profesionales de la salud

Walgreens apoya a aproximadamente 250,000 profesionales de la salud a través de sus servicios y asociaciones farmacéuticas.

• Los farmacéuticos sirvieron: 135,000
• Red de médicos: 75,000
• Enfermera practicantes: 40,000

Pacientes de enfermedades de ancianos y crónicos

Walgreens atiende a aproximadamente 15 millones de pacientes con afecciones crónicas, con un enfoque significativo en las poblaciones de Medicare y Medicaid.

Condición crónica	Población de pacientes
Diabetes	4.2 millones
Hipertensión	5.6 millones
Cardiopatía	3.1 millones

Clientes de atención médica corporativa e institucional

Walgreens administra los servicios de atención médica para más de 500 clientes corporativos y socios institucionales, generando $ 12.4 mil millones en ingresos de atención médica corporativa en 2023.

• Fortune 500 Clientes corporativos: 175
• Asociaciones del sistema de salud: 250
• Valor anual del contrato de salud corporativo: promedio de $ 24.8 millones

Individuos centrados en el bienestar

Walgreens se dirige a aproximadamente 35 millones de consumidores conscientes de la salud a través de sus programas de bienestar y plataformas de salud digital.

Segmento de bienestar	Base de usuarios
Usuarios de la plataforma de salud digital	8.2 millones
Clientes de suplementos de nutrición	6.5 millones
Programa de seguimiento de fitness	4.3 millones

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocio: Estructura de costos

Adquisición de inventario farmacéutico

Costos de adquisición de inventario farmacéutico total para el año fiscal 2023: $ 59.1 mil millones

Categoría de inventario	Costo anual
Medicamentos recetados	$ 42.3 mil millones
Medicamentos de venta libre	$ 8.7 mil millones
Suministros médicos	$ 8.1 mil millones

Operaciones y mantenimiento de la tienda minorista

Gastos totales de operaciones anuales de tiendas minoristas: $ 22.6 mil millones

• Número de tiendas minoristas: 9.021
• Costo promedio de mantenimiento de la tienda por ubicación: $ 2.5 millones anuales
• Gestión de servicios públicos y de instalaciones: $ 3.4 mil millones

Salarios de empleados y compensación profesional de la salud

Compensación anual total de empleados: $ 18.3 mil millones

Categoría de empleado	Compensación anual
Personal minorista	$ 7.6 mil millones
Farmacéuticos	$ 4.9 mil millones
Empleados corporativos	$ 5.8 mil millones

Tecnología y desarrollo de plataforma digital

Inversión de tecnología anual total: $ 1.2 mil millones

• Desarrollo de plataforma digital: $ 650 millones
• Infraestructura de ciberseguridad: $ 280 millones
• Mantenimiento de la plataforma de comercio electrónico: $ 270 millones

Gastos de marketing y adquisición de clientes

Gastos de marketing anuales totales: $ 2.7 mil millones

Canal de marketing	Gasto anual
Marketing digital	$ 1.1 mil millones
Publicidad tradicional	$ 890 millones
Programas de fidelización de clientes	$ 710 millones

Walgreens Boots Alliance, Inc. (WBA) - Modelo de negocios: flujos de ingresos

Venta de medicamentos recetados

En el año fiscal 2023, Walgreens Boots Alliance reportó ventas de medicamentos recetados de $ 122.0 mil millones. La Compañía procesó aproximadamente 1.100 millones de recetas durante este período.

Segmento de receta	Ingresos ($ mil millones)	Porcentaje de ingresos totales
Ventas de recetas minoristas	86.5	39.2%
Al por mayor farmacéutico	35.5	16.1%

Ingresos de productos de venta libre

Las ventas de productos de venta libre (OTC) generaron $ 18.4 mil millones en ingresos para Walgreens en el año fiscal 2023.

• Las mejores categorías de productos de OTC incluyen:
• Medicamentos de alivio del dolor
• Tratamientos de frío y gripe
• Vitaminas y suplementos
• Productos de cuidado personal

Servicios y consultas de atención médica

Los ingresos por servicios de atención médica alcanzaron los $ 5.2 mil millones en el año fiscal 2023, con un crecimiento significativo de:

Tipo de servicio	Ingresos ($ millones)
Vaccinaciones Covid-19	1.6
Inmunizaciones de rutina	1.1
Servicios clínicos	2.5

Distribución al por mayor farmacéutica

La distribución al por mayor farmacéutica a través de Alliance Healthcare generó $ 35.5 mil millones en ingresos para el año fiscal 2023.

• Cobertura internacional de distribución farmacéutica en 13 países
• Atendiendo más de 170,000 farmacias y proveedores de atención médica

Plataforma de salud digital y servicios de tecnología

Los ingresos de la plataforma de salud digital totalizaron $ 2.3 mil millones en el año fiscal 2023.

Servicio digital	Ingresos ($ millones)
Recargas de receta en línea	850
Consultas de telesalud	750
Monitoreo de la salud digital	700

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Value Propositions

You're looking at the core reasons customers choose Walgreens Boots Alliance, Inc. (WBA) over the competition right now. It's about blending the local corner store feel with sophisticated healthcare delivery, so you get both convenience and specialized medical support.

Convenient, trusted, and accessible local healthcare destination.

Walgreens Boots Alliance, Inc. maintains a massive physical footprint, which is a key part of its value. As of March 2025, you could find over 8,700 Walgreens locations across the U.S.. This physical presence is augmented by digital health services, offering virtual care in 30 states, making that care accessible to nearly 90% of the U.S. population. The company is actively optimizing this footprint, planning to close 500 stores in fiscal year 2025 as part of a larger Footprint Optimization Program.

The value proposition here is accessibility, supported by:

• Over 8,700 U.S. Walgreens locations as of March 2025.
• Virtual care available in 30 states.
• Delivery options, including two-hour service from approximately 800 stores.

Integrated primary care and specialty pharmacy services (Shields Health Solutions).

The integration of Shields Health Solutions is central to WBA's high-value healthcare offering, especially for complex, high-cost medications. Shields works directly with health systems to manage their specialty pharmacy needs. This business unit partners with more than 80 health system partners nationwide, which represents approximately 1,000 hospitals. The impact on payer access is significant; Shields has unlocked $11B of incremental payer access since 2021.

Here's a look at some of the operational and financial outcomes Shields delivers for its partners:

Metric	Value/Rate	Context
Incremental Payer Access Unlocked (Since 2021)	$11B	Total value unlocked for health systems
Health System Partners	Over 80	Number of partners nationwide
Average Time to Therapy	~2 days	Operational efficiency metric
Medication Adherence Rates	92.3%	Clinical outcome metric
Projected Partner Pharmacy Growth	35-40%	Sustainable growth driven by the care model

The goal is to accelerate specialty pharmacy success by breaking down barriers to affordable care, so you see improved patient outcomes and system-wide growth.

One-stop shop for prescription drugs, over-the-counter (OTC) medicine, and retail essentials.

The traditional retail component remains a core value, though it's increasingly balanced by pharmacy volume. In the first quarter of fiscal year 2025, comparable pharmacy sales grew 12.7%, driven by brand inflation and prescription volume. To be fair, comparable retail sales decreased 2.4% in Q3 2025, impacted by weaker sales in grocery, household, health and wellness, and beauty. However, the pharmacy side is robust, with total prescriptions filled (including immunizations, adjusted to 30-day equivalents) reaching 316.3 million in Q1 FY2025.

Key prescription volume statistics from Q1 FY2025 include:

• Total prescriptions filled (30-day equivalent): 316.3 million.
• Comparable prescriptions filled (excluding immunizations): Growth of 3.5%.
• Comparable pharmacy sales growth: 12.7%.

Personalized value and offers through the myWalgreens rewards program.

The myWalgreens program is designed to be a personalized digital platform, moving beyond the old points system to offer direct cash rewards. Members earn 1 percent in Walgreens Cash rewards on most eligible purchases made in-store and online, including pharmacy prescriptions and services (with some state exceptions). For WBA's own products, the reward is higher at 5 percent in Walgreens Cash rewards on Walgreens-branded items.

This focus on own-brand products is a deliberate strategy to boost profitability, as seen in the penetration rate:

Metric	Value
Own-Brand Penetration (Q1 FY2025)	17.8%
Increase in Penetration (Basis Points)	75
Planned New Own-Brand Products (FY2025)	Over 300

The program also drives engagement through personalized offers and regional alerts based on location and shopping habits, helping to tailor the value proposition to the individual you.

High-volume prescription capacity, filling 316.3 million scripts in Q1 FY2025.

This number underscores the sheer scale of WBA's dispensing operation. The 316.3 million total prescriptions filled in Q1 FY2025, adjusted to 30-day equivalents, represents a 1.5% increase year-over-year. This high volume is supported by operational improvements, such as Micro-Fulfillment Centers (MFCs) serving approximately 4,800 stores, which saw shipped volumes up 23% year-on-year, and a cost-to-fill down 13%. These efficiencies help free up pharmacists for clinical services.

Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Customer Relationships

The relationship Walgreens Boots Alliance, Inc. (WBA) maintains with its customers is segmented by the service being delivered, moving from highly automated transactions to dedicated, personal care interactions.

Automated, transactional relationship for prescription refills and retail purchases

For routine prescription fulfillment, Walgreens Boots Alliance, Inc. relies heavily on centralized automation to process high volumes, creating a fast, transactional touchpoint for the majority of refills. The company has been aggressively scaling its network of micro-fulfillment centers (MFCs) to handle this volume. As of May 2025, the network of 12 MFCs supported over 5,000 stores across the country. These high-tech facilities were fulfilling more than 3.5 million prescriptions weekly, which equates to approximately 16 million prescriptions filled each month.

This automation directly impacts the in-store experience by shifting workload away from the counter. At locations serviced by these facilities, MFCs manage approximately 40% of a store's total prescription volume. This operational shift is estimated to have reduced the cost per prescription by 13%. The initial goal was to have as much as half of the total prescription volume filled at these automated centers by 2025.

Metric	Value	Context/Date
Micro-Fulfillment Centers (MFCs) in Operation	12	As of May 2025
Stores Supported by MFC Network	Over 5,000	As of May 2025
Prescriptions Fulfilled Weekly (MFCs)	Over 3.5 million	As of May 2025
Cost Reduction per Prescription (Automation)	13%	Reported efficiency gain

Personalized digital engagement via the myWalgreens app and email

Digital channels are central to maintaining ongoing customer engagement and driving loyalty, primarily through the myWalgreens platform. The myWalgreens loyalty program boasts a substantial base, with more than 113 million active program members as of August 31, 2023. The Walgreens mobile app itself is trusted by over 13 million customers for managing health and shopping needs.

This digital relationship is structured around rewards and convenience:

• Earn unlimited 1% Walgreens Cash rewards storewide, even at the pharmacy.
• Earn unlimited 5% Walgreens Cash rewards per dollar on Walgreens branded products.
• Digital coupons and personalized deals are delivered to drive engagement and sales.

In the international segment, digital sales are also a key relationship driver; Boots.com sales grew 19.5% in fiscal 2025, making up over 20% of Boots' total retail sales.

Dedicated, high-touch relationships for specialty pharmacy and primary care patients

For complex health needs, the relationship shifts to a dedicated, high-touch model, primarily through the U.S. Healthcare segment investments. This segment is a growing part of the overall business, reporting first quarter fiscal 2025 sales of $2.2 billion.

The growth within these specialized areas demonstrates the focus on deeper patient relationships:

• VillageMD, the primary care network, saw sales increase 9% year-over-year in Q1 fiscal 2025.
• Shields Health Solutions, focused on specialty pharmacy, saw sales increase 30% in Q1 fiscal 2025.

This focus allows pharmacists to spend more time on patient advising and clinical needs, as automation handles routine tasks.

Self-service options for photo printing and online order pickup

Self-service options cater to customers prioritizing speed and control over their retail interactions. The digital platforms facilitate quick fulfillment choices that blend the online and physical experience. For customers using the app or website, pickup orders are advertised as ready in as little as 30 minutes curbside, drive-thru, or in-store. For those needing items delivered, the service promises delivery in as little as 1 hour.

The photo services remain a key self-service offering, with the Walgreens App allowing customers to bring ideas to life with custom photo prints, ready the same day.

Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Channels

You're looking at how Walgreens Boots Alliance, Inc. (WBA) gets its value proposition to the customer base as of late 2025. It's a mix of old-school real estate and digital integration, honestly, and the numbers show where the focus is shifting.

Physical Retail Stores (Walgreens and Boots UK)

The physical footprint remains the backbone, though it's actively being optimized. For Walgreens in the U.S., the count is tightening up as part of a major restructuring. As of December 1, 2025, there were 8,054 Walgreens pharmacies in the United States, following a plan to close 500 locations during fiscal year 2025. This optimization aims for a healthier store base, focusing investment on the profitable locations, which the CEO noted number around 6,000.

Across the pond, Boots UK is also managing its portfolio. While the company operated 1,840 stores as of August 31, 2024, a more recent figure from May 31, 2025, indicates they have over 1,800 stores, following a multi-year consolidation program. The Boots UK segment is a significant part of the international business, with its Q3 FY2025 sales growing 5.0 percent on a constant currency basis.

The in-store clinics represent a key channel for moving beyond pure retail. The Village Medical at Walgreens strategy saw an initial goal of 600 practices by 2025. However, the current strategy involves a reduction, with Walgreens announcing the closure of more than 160 VillageMD clinics as of early 2024, while evaluating options for other units like Summit Health-CityMD.

Here is a snapshot of the physical and digital scale as of the latest reporting periods:

Channel Component	Metric/Count	Latest Data Point/Date	Source Context
Walgreens U.S. Pharmacies	8,054	December 1, 2025	Current operating count
Walgreens FY2025 Planned Closures	500	Fiscal Year 2025	Part of a larger 1,200 store closure plan
Boots UK Stores	Over 1,800	May 31, 2025	Reflects portfolio management from a previous high of 2,232 in August 2022
VillageMD Clinic Reductions	Over 160 shut	Announced April 2024	Part of a reevaluation of the expansion plan

E-commerce platforms (Walgreens.com and Boots.com)

Digital sales are a growing component, particularly for Boots in the UK. Boots.com is cited as the UK's number one most visited health and beauty website. For the third quarter of fiscal 2025, Boots.com sales grew 18.7 percent year-over-year, representing 17 percent of Boots total retail sales. This growth is part of a trend, as Q2 FY2025 saw growth of 19.5 percent, making up over 20 percent of retail sales.

For Walgreens in the U.S., e-commerce is captured within the U.S. Retail Pharmacy segment comparable sales, which were up 10.3 percent in Q3 FY2025. The company's overall Q3 FY2025 sales reached $39.0 billion.

Mobile application for prescription management and digital coupons

The mobile channel is quantified through user engagement metrics, especially for the Boots brand. The Boots app had 8.4 million active users as of May 31, 2025. This digital tool supports prescription management, which is a core function. Across the U.S. pharmacy operations in Q1 FY2025, total prescriptions filled, adjusted to 30-day equivalents, reached 316.3 million, a 1.5 percent increase year-over-year. The company is number one for dispensing prescription items in the UK, handling millions per week.

The digital coupon and engagement strategy is also supported by the Boots Advantage Card program, which boasts over 17 million active members as of May 31, 2025.

Mail-order pharmacy services

While Walgreens U.S. comparable prescriptions filled (excluding immunizations) increased 3.9 percent in Q2 FY2025, specific, standalone financial or volume data for dedicated mail-order pharmacy services is not explicitly broken out in the latest public reports available to detail this channel separately from digitally initiated or standard retail pharmacy fulfillment.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Customer Segments

Walgreens Boots Alliance, Inc. (WBA) serves a highly diverse customer base across its U.S. Retail Pharmacy, International, and U.S. Healthcare segments.

The core customer base is anchored by the need for accessible health services and everyday retail convenience. As of August 31, 2024, approximately 78% of the U.S. population lived within a five-mile radius of a Walgreens or Duane Reade store, underscoring this mass-market reach.

The company also focuses on specific patient populations and strategic partners:

• Mass market retail shoppers seeking convenience and value.
• Chronic and acute patients requiring regular prescription medications.
• Price-sensitive consumers, including approximately 45% of low-income shoppers.
• Healthcare plan sponsors and providers utilizing CareCentrix and Shields.
• International retail and pharmacy customers (primarily Boots UK).

The scale of these segments can be seen in the following operational and financial metrics from the latest available reports for fiscal year 2025:

Customer Segment Focus	Metric	Value/Rate	Period/Date
Mass Market Retail Reach (US)	Number of U.S. Stores	More than 8,700	March 2025
Mass Market Retail Reach (US)	Population within 5 miles of a store	78%	August 31, 2024
Chronic/Acute Patients (US Pharmacy)	U.S. Retail Pharmacy Segment Revenue	$111.5 billion	Fiscal Year 2024
Healthcare Partners (U.S. Healthcare)	Shields Sales Growth (Q3 FY25)	Increased 24.8%	Q3 Fiscal 2025
Healthcare Partners (U.S. Healthcare)	CareCentrix Sales Growth (Q3 FY25)	Increased 11.6%	Q3 Fiscal 2025
International Customers (Boots UK)	Comparable Retail Sales Growth (Q3 FY25)	6.0%	Q3 Fiscal 2025
International Customers (Boots UK)	Boots.com Sales as % of Total Retail Sales	15%	Fiscal 2024
International Customers (Boots UK)	Online Sales as % of Total Retail Sales	20%	Three months ending February 2025

The U.S. Retail Pharmacy segment remains a massive driver, with comparable pharmacy sales showing strength, while the front-end retail sales have seen weakness. For the U.S. Healthcare segment in Q3 fiscal 2025, total sales were $2.1 billion.

The Boots UK segment continues to show growth momentum, with comparable pharmacy sales increasing 5.4% on a constant currency basis in Q3 fiscal 2025, and its digital channel is significant, with Boots.com sales growing 18.7% year-on-year in that quarter.

Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Cost Structure

You're looking at the cost side of Walgreens Boots Alliance, Inc. (WBA) as they navigate that tricky pivot from traditional retail to integrated healthcare. The numbers show where the biggest drains on cash and profitability are right now, based on the first nine months of fiscal year 2025 (9M FY2025) ending May 31, 2025.

The single largest component of cost is tied directly to sales volume. High cost of revenue, primarily product procurement for both prescription drugs and general retail inventory, eats up the vast majority of the top line. For 9M FY2025, the Gross Profit Margin was only 17.3%, meaning that roughly 82.7% of the $117.0 billion in total sales went to cover the cost of the goods sold. This high ratio reflects the lower-margin nature of high-volume prescription fulfillment and the competitive retail environment.

Next up are the fixed and semi-fixed costs associated with running the physical footprint. Significant store operating expenses are a constant pressure point. While specific rent figures aren't broken out separately in the latest summaries, payroll is a major driver of operating cost inflation. For instance, in the International segment during Q1 FY2025, cost inflation was primarily driven by payroll. The overall Operating Expenses for 9M FY2025 were reported as -$23.1B USD.

The balance sheet and cash flow statements are heavily impacted by one-time, non-cash charges and major legal settlements. These items significantly distort GAAP profitability. You saw a major hit in Q2 FY2025 with a $3.0 billion non-cash impairment charge related to VillageMD goodwill and other long-lived assets, which resulted in a $1.9 billion charge attributable to Walgreens Boots Alliance, net of tax and non-controlling interest. This reflects the ongoing strategic reassessment of the primary care investment.

Cash flow is definitely feeling the weight of litigation. Substantial legal payments are a major cash outflow. For the first nine months of fiscal 2025, operating cash flow was negatively impacted by $1.4 billion of legal payments, primarily related to Everly and opioid-related settlements. That's a huge chunk of cash used before even considering capital expenditures.

Here's a quick look at the key cost drivers for the 9M FY2025 period:

• Cost of Revenue (Implied): Approximately 82.7% of sales.
• Total Operating Expenses: $23.1 billion magnitude.
• Major Non-Cash Charge (Q2 FY2025): $3.0 billion VillageMD goodwill impairment.
• Cash Legal Payments (9M FY2025): $1.4 billion.

The company is actively investing in its future, which shows up as an expense category. Technology and digital transformation investments are part of the ongoing turnaround. For example, in Q1 FY2025, technology investments were cited as a factor partially offsetting adjusted operating income gains in the International segment, alongside cost inflation.

To put the scale of these costs into perspective, here is a comparison of key financial metrics for the nine-month period:

Metric	Amount (9M FY2025)	Context
Total Sales	$117.0 billion	Top-line revenue base.
Gross Profit	$20.220 billion	Sales minus Cost of Revenue.
Operating Loss (GAAP)	$5.8 billion	After all operating expenses, before interest/tax.
Net Loss (GAAP)	$3.3 billion	The bottom-line result.
Cash Used by Operating Activities (Net)	$245 million	Net cash flow from operations.

The pressure from these costs is evident in the GAAP results, where the operating loss for 9M FY2025 reached $5.8 billion. Finance: draft 13-week cash view by Friday.

Walgreens Boots Alliance, Inc. (WBA) - Canvas Business Model: Revenue Streams

You're looking at how Walgreens Boots Alliance, Inc. (WBA) brings in the money, focusing strictly on the hard numbers as of late 2025. It's a mix of dispensing medicine and selling everyday goods, plus a growing healthcare services piece.

The largest chunk of revenue definitely comes from prescription drug sales, which is the core of the U.S. Retail Pharmacy segment. For the third quarter of fiscal 2025, this segment alone pulled in $30.7 billion in sales. Within that, pharmacy sales were up 11.8% year-over-year, largely thanks to branded drug inflation and the mix of drugs being dispensed.

Retail sales of front-end merchandise-think beauty, health, and wellness items you grab off the shelf-are another key stream, though they've seen some pressure. In that same Q3 FY2025 period, retail sales in the U.S. Retail Pharmacy segment actually declined by 5.3%. Still, the overall segment sales growth was strong enough to push total Q3 sales to $39.0 billion.

The U.S. Healthcare segment is a distinct revenue driver, which hit $2.1 billion in Q3 FY2025. This stream includes fees from providing clinical services, like immunizations and testing, though the segment's performance is tied to its specific businesses.

Here's a quick look at the segment sales breakdown from the third quarter of fiscal 2025:

Segment	Q3 FY2025 Sales Amount	Year-over-Year Sales Change (Reported)
U.S. Retail Pharmacy	$30.7 billion	Up 7.8%
International	$6.2 billion	Up 7.8%
U.S. Healthcare	$2.1 billion	Slightly down

For the full picture, Walgreens Boots Alliance, Inc. projected its full fiscal year 2025 sales to be between $147 billion and $151 billion. That's the big-picture target for the year, even though the company later withdrew formal guidance due to the pending acquisition.

Revenue from the U.S. Healthcare operations is diversified across its components, which contribute to those clinical services fees and other arrangements. You can see the variation in the Q3 performance of the sub-components:

• CareCentrix sales increased 11.6%.
• Shields sales increased 24.8%.
• VillageMD sales decreased 6.5%.